Beijing Chunlizhengda Medical Instruments Co., Ltd. (Stock Code: 1858) – 2025 Annual Report Detailed Analysis

1. Financial Performance Surges in 2025

• Revenue Growth: The Company reported revenue of RMB 1,045.77 million in 2025, marking a significant year-on-year increase of 29.77%.
• Net Profit: Net profit attributable to shareholders soared to RMB 272.54 million, up 118.05% compared to 2024. After deducting non-recurring profit and loss, net profit reached RMB 255.53 million, up 170.29% year-on-year.
• EPS: Basic and diluted earnings per share were RMB 0.71. EPS after deducting non-recurring profit and loss was RMB 0.67, reflecting increases of 115.15% and 168% respectively.
• Assets: Total assets increased to RMB 3,661.13 million, up 5.64%. Net assets attributable to shareholders also rose to RMB 2,985.47 million, an increase of 5.87%.
• Profit Distribution: The Company proposes a final cash dividend of RMB 1.50 per 10 shares (tax inclusive), up from RMB 0.49 in 2024. The total cash dividend for the year will account for 50.48% of net profit attributable to ordinary shareholders.

2. Key Business Developments and Strategic Initiatives

• Marketing and Expansion: The Company successfully expanded its centralized-procurement products and entered international markets, driving sales volume and profitability.
• Cost Efficiency: Internal measures for cost reduction and efficiency improvement boosted competitiveness and profitability.
• Product Innovation: Ongoing R&D led to innovations in orthopedics, dental, PRP (Platelet-Rich Plasma) products, and orthopedic power tools. The Company also strengthened its intellectual property protection and patent reward mechanisms.
• Share Repurchase: The Company repurchased 508,706 shares in 2025, using its funds for employee stock ownership plans and equity incentives. Total repurchased shares reached 1,376,851 and were held in the A-share repurchase account.
• Use of IPO Proceeds: Net proceeds from the A-share offering (over RMB 1,067 million) were allocated to integrated construction projects, R&D centers, marketing network construction, and working capital. These projects are expected to be ready by December 2026.

3. Dividend Policy & Shareholder Returns

• Increased Dividend: The Company proposes to pay RMB 1.50 per 10 shares (tax inclusive) as a final dividend. Total cash dividends for the year will be RMB 137.59 million, covering over 50% of net profit attributable to ordinary shareholders.
• Dividend Payment Details: Final dividend for H Shares will be paid in HK dollars, and A Shares in RMB. The exchange rate will be the mid-rate published by the People’s Bank of China seven business days before dividend approval. Payment is expected by 30 June 2026.
• General Meeting: The annual general meeting is scheduled for 26 May 2026, where the dividend proposal will be reviewed and approved.

4. Corporate Governance & Compliance

• Governance Improvements: The Company revised its internal governance system to align with CSRC and SSE regulations.
• ESG Commitment: The Company published its 2025 ESG report and remains committed to fulfilling social responsibilities and sustainable development.
• Transparency: Enhanced information disclosure and investor communication channels, including phone, online meetings, and Shanghai Stock Exchange e-Interaction.
• Risk Management: The report notes potential risks related to national volume-based procurement policies, which may affect product pricing and gross margins. The Company is actively monitoring policy trends and enhancing operations to mitigate impacts.
• Compliance Issues: Minor non-compliance instances were addressed through strengthened internal reviews and targeted training.

5. Significant Investments and Capital Management

• Structured Deposits: The Company invested in structured deposit products from Bank of Beijing using temporarily idle capital from IPO proceeds and internal resources, aiming to enhance capital returns while maintaining liquidity.
• Gearing Ratio: The Company maintains a low gearing ratio (18.41%), with no interest-bearing debt, optimizing capital structure and minimizing financing costs.

6. Shareholding Structure & Insider Ownership

• Major Shareholders: Mr. Shi Chunbao (Executive Director) and Ms. Yue Shujun collectively hold over 50% of the Company’s shares, both A and H Shares. Other substantial shareholders include Panmao (Shanghai) Equity Investment Center and Taiping Assets Management (HK).
• Director Ownership: Directors and their associates reported no competing business and no significant interests in top suppliers or customers.

7. Outlook for 2026

• Focus on Main Business: The Company will further optimize and strengthen its orthopedic product line, continue investing in R&D for diversified products, improve patent management, and strive for high-quality and sustainable growth.
• Corporate Governance: Continued improvement of governance structures, internal control systems, and integration of sustainability into strategic decisions.
• Investor Relations: Ongoing commitment to transparent information disclosure and effective investor communication.

8. Risks and Uncertainties

• Centralized Procurement Risks: Possible reduction in product prices and gross margins due to national procurement policies. The Company is actively monitoring these policies and diversifying its market presence.
• Market Risks: Exposure to interest rate and foreign currency risks is minimal due to business concentration in mainland China and absence of interest-bearing debt.
• Credit Risk Management: Bank balances are held at high-credit institutions. Receivables are closely monitored to mitigate potential credit losses.

9. Other Notable Events

• No Material Litigation: The Company was not involved in any significant litigation or arbitration during 2025.
• Auditor’s Reappointment: WUYIGE Certified Public Accountants LLP audited the report and is eligible for reappointment in the next cycle.
• Segment Reporting: The Company operates as a single reportable segment—manufacture and trading of surgical implants and related products.

10. Price Sensitive & Share Price Implications

• Strong Financial Results: The substantial growth in revenue, net profit, and EPS, coupled with a generous dividend payout, could positively impact share price and investor sentiment.
• Dividend Increase: The significant hike in dividend per share is likely to attract income-focused investors and boost market confidence.
• Share Repurchase: The ongoing share buyback program and repurchase for employee incentive plans indicate management’s confidence in the Company’s future prospects.
• R&D and Market Expansion: Continued investment in R&D, new product lines, and international expansion signals long-term growth potential, which may drive share valuation higher.
• Risk Factors: Investors should monitor potential impacts from centralized procurement and policy changes, which could affect margins and pricing in the coming years.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell shares of Beijing Chunlizhengda Medical Instruments Co., Ltd. Investors should conduct their own due diligence and consult professional advisors before making investment decisions. The Company’s future performance is subject to risks and uncertainties, including but not limited to regulatory changes, market risks, and operational challenges.

View CHUNLI MEDICAL Historical chart here